Le Lézard
Classified in: Health, Science and technology
Subjects: Stock Sale/Buyback, Share Issue

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 31,515 restricted stock units of Atara's common stock to four newly hired employees and stock options to purchase an aggregate of 15,227 shares of Atara's common stock to one such newly hired employee. These awards were approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of July 1, 2022, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options have a ten-year term and an exercise price of $8.30 per share, equal to the per share closing price of Atara's common stock as reported by Nasdaq on July 1, 2022.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.


These press releases may also interest you

at 07:55
BIONIK Laboratories Corp. , a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for the first...

at 07:50
The Biden administration has prioritized goals relating to climate change, equity, and infrastructure, particularly with the signing of a $1.2 trillion bill to rebuild America's aging infrastructure. To take action on many of these initiatives...

at 07:50
MemryX Inc., a pioneering start-up that designs breakthrough silicon for artificial intelligence (AI) processing for edge devices, announced today it has begun customer sampling of its revolutionary MX3 AI Accelerator. The MX3 was created to become...

at 07:46
CNSI, a leading provider of innovative healthcare technology products and solutions, announced today the addition of two highly experienced industry veterans to its Business Development team: Brian Wilbon joins as Vice President in the newly created...

at 07:45
NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022. The company...

at 07:45
The "Global Digital Grid Guidebook" report has been added to ResearchAndMarkets.com's offering. Value generated by grid optimization digital solutions will reach $22.27 billion in 2025. The ongoing global and regional efforts to decentralize and...



News published on 1 july 2022 at 20:00 and distributed by: